Departed
Vincent LeVien
Director
CELU ·
Celularity Inc
Effective June 26, 2026, Vincent LeVien resigned as a member of the Company’s Board of Directors.
Ready 8-Ks
50
Latest filing
June 30, 2026, 9:00 AM ET
Top materiality
0.85
Event mix
other_material ×23 · regulatory ×9 · leadership ×8
Sentiment
8 pos · 14 neg · 28 neu
Latest earnings
▼ miss 2025-Q1
Executive change
recent →
Recent 8-K filings for CELU
Highest-materiality recent filing
Celularity retires all $41.6M senior secured debt via IP sale and license-back deal
- Retired all $32M principal plus $9.6M accrued interest on senior secured loans for total $41.6M.
- Sold IP assets to Celeniv for $33,812,230; licensed back exclusively with five-year repurchase option.
-
Celularity enters $1M secured loan from Barach trust; director LeVien resigns
Loan of $1,000,000 from Philip & Daniele Barach Family Trust (affiliated with >5% owner) at 4% interest, matures in 30 days or upon receipt of proceeds from financing.
-
Celularity appoints Steven Gordon as COO, Harold Fletcher as CLO; Gordon also joins Board
Steven N. Gordon appointed Chief Operating and Administrative Officer, effective June 19, 2026.
-
Celularity receives Nasdaq deficiency notice for MVLS below $35M; 180 days to comply
Nasdaq notified Celularity on June 9, 2026, that MVLS was below $35M for 30 consecutive business days.
-
Celularity names Rick Gonzalez Chief Commercial Officer, advances longevity and cenplacel-L focus
Rick Gonzalez appointed CCO effective May 29, 2026, reporting to Chairman & CEO Robert Hariri.
-
Celularity settles Helena dispute; pays $500K cash, $500K installments, assigns $2.5M NEXGEL note
Settlement with Helena Global resolves claims over Series A convertible preferred stock and promissory note.
-
Celularity closes $13.3M NexGel asset sale; Helena default notice on $1.97M note
Closed asset sale to NexGel for $13.3M ($8.3M cash + $5M note), retired ~$13M debt.
-
Celularity licenses biomaterials portfolio for up to $35M; retains manufacturing, cuts costs
Up to $35M cash: $15M upfront plus $20M milestone payments based on net sales targets.
-
Celularity CFO Joseph DosSantos departs; John Sprague named acting CFO
Joseph DosSantos left as SVP Finance and Acting CFO on Feb 27, 2026 for personal reasons.
-
Celularity amends SVP Haines' agreement; severance doubled, COBRA extended, equity accelerated
Comp Committee approved amendment to John Haines' employment agreement on Jan 16, 2026.
-
Celularity closes $10M financing with Philip A. Barach; issues senior secured and convertible notes
Gross proceeds at closing: $10.0M; potential additional $2.0M subject to conditions.
-
Celularity annual meeting: directors elected despite majority withheld; equity plan increase fails
Class I directors Peter Diamandis, Diane Parks, Geoffrey Ling elected; each received >4.5M votes for but >9.5M withheld.
-
Celularity receives FDA warning letter over Interfyl marketing claims
FDA warning letter received Dec 1, 2025, regarding marketing material for Interfyl (human connective tissue matrix).
-
Celularity raises $2M initial tranche in $6.67M private placement of Series A Preferred and warrants
Series A Preferred shares sold at 90% of stated value; $2M initial tranche closed Oct 24, 2025.
-
Nasdaq confirms Celularity compliant with listing rule after late 10-Qs; deficiency closed
Nasdaq notified Celularity on Sept 2, 2025 that it has regained compliance with Listing Rule 5250(c)(1).
-
Celularity retires all $41.6M senior secured debt via IP sale and license-back deal
Retired all $32M principal plus $9.6M accrued interest on senior secured loans for total $41.6M.
-
Celularity invests $2.9M in Defeye preferred stock; gets Nasdaq extension to Aug 31 for late filings
Acquired 7,198.6 shares of Defeye Series Seed-2 Preferred Stock for $2.89M in product purchase credits.
-
Celularity issues $6.81M promissory note and warrant to investor Lim Kok Thay
Issued $6,812,230 promissory note to Lim Kok Thay, 2% interest, matures March 21, 2026, secured by all company assets.
-
Celularity raises $2M via private placement of 1.23M shares and warrants
Issued 1,230,769 shares of common stock and warrants to purchase 1,230,769 shares at $1.625 per unit.
-
Celularity reprices warrants for Starr and RWI, issues new warrants under forbearance amendments
Repriced Starr warrants to $1.692/share; issued new warrant for 100,000 shares.
-
Celularity raises $1.035M in private placement of 739,286 shares at $1.40/share
Issue and sale of 739,286 shares of Class A common stock at $1.40 per share for gross proceeds of $1,035,000.
-
Celularity terminates CFO Beers without cause; names DosSantos interim CFO
CFO David Beers terminated without cause effective June 10, 2025; severance subject to release.
-
Celularity appoints Vincent LeVien as Class II director, effective June 5, 2025
Vincent LeVien appointed to Board as Class II director, serving until 2026 Annual Meeting.
-
Celularity extends convertible note maturity to Aug 15, 2025; issues 100K shares
Maturity of Convertible Promissory Note (dated March 13, 2024) extended from May 12, 2025 to August 15, 2025.
-
Director Dean Kehler resigns from Celularity board effective May 14, 2025
Dean Kehler resigned as a director of Celularity Inc. on May 14, 2025.
-
Celularity reports 2024 revenue of $54.2M, up 138% YoY; operating loss narrows 80%
Net revenues $54.2M, up 138.1% YoY; product sales in wound care up 168.7% to $35.3M.
-
Celularity regains Nasdaq compliance after paying $70,000 past due fee
On April 30, 2025, Nasdaq notified Celularity that its $70,000 past due fee was paid.
-
Celularity receives Nasdaq notice for late 10-K filing; must submit compliance plan by June 16, 2025
Failed to file 2024 Form 10-K by extension deadline; Nasdaq issued notice of non-compliance on April 16, 2025.
-
Celularity extends note maturity to May 12, 2025; issues 100k shares as forbearance fee
Extended convertible note maturity from March 13 to May 12, 2025; Yorkville forbears from default until then.
-
Celularity enters manufacturing collaboration with BlueSphere Bio for AML cell therapy
Master Services Collaboration Agreement to manufacture BlueSphere's TCR T cell therapies for AML.
-
Celularity extends loan maturities to Feb 2026 via binding term sheets with RWI and Starr
RWI binding term sheet covers three loans totaling $27M principal; maturity extended to Feb 15, 2026.
-
Celularity amends warrant exercise price to $2.07, receives $2.46M gross proceeds
Amended exercise price of two warrants from $2.49 to $2.07 per share on January 24, 2025.
-
Celularity private placement terminated after investor fails to pay subscription amount
Celularity terminated securities purchase agreement with institutional investor for 1,263,157 shares and warrants at $2.375/share.
-
Celularity raises $3.0M via private placement of common stock and warrants
Issued 1,263,157 shares of Class A common stock and warrants to purchase up to 1,263,157 shares at $2.375 per unit.
-
Robert J. Hariri elected with 10,250,294 votes for; 53,960 withheld; 3,285,202 broker non-votes.
-
Celularity raises up to $1M via convertible notes and warrants; initial $500K closed
Issued $500,000 in 8% unsecured senior convertible notes due one year; interest rises to 10% on default.
-
Celularity receives Nasdaq delisting notice for late Q3 2024 10-Q filing
Failed to file Q3 2024 10-Q by Nov 19 extension; Nasdaq issued non-compliance notice on Nov 21, 2024.
-
Celularity sets 2024 annual meeting for Dec 19; record date Nov 8
2024 Annual Meeting of Stockholders scheduled for December 19, 2024.
-
Celularity raises FY 2024 net sales guidance to $54-60M; October sales hit record $8.3-8.9M
Raises full-year 2024 expected net sales guidance to $54M-$60M from $50M-$56M, citing strong advanced biomaterial sales.
-
Celularity expects H1 2024 biomaterial revenue >$24M, Rebound >$9M; reaffirms $50-56M FY guidance
Preliminary net revenue from biomaterial products exceeds $24M for six months ended June 30, 2024, surpassing full-year 2023 sales.
-
Celularity faces Nasdaq suspension Oct 25 for delinquent 10-Q filings; plans appeal
Nasdaq notified Celularity on Oct 16, 2024, that trading will be suspended Oct 25 due to failure to file Q1 and Q2 2024 10-Qs by Oct 14 extension deadline.
-
Celularity acquires Rebound placental matrix product from Sequence LifeScience for $5.5M
Total consideration $5.5M: $1M upfront cash, up to $4M monthly milestone payments (20% of net sales), and $500K credit.
-
Celularity CMO Adrian Kilcoyne resigns effective August 6, 2024
Adrian Kilcoyne, EVP and Chief Medical Officer, resigns to pursue other opportunities.
-
Celularity appoints Richard J. Berman to Board; reduces board from 7 to 6
Richard J. Berman appointed as Class II director, effective Aug 27, 2024, to fill vacancy left by Robin L. Smith.
-
Nasdaq notified Celularity on Aug 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to failure to timely file Q2 2024 10-Q and continued delinquency in Q1 2024 10-Q.
-
Celularity dismisses Deloitte as auditor, engages EisnerAmper; director Marc Mazur resigns
Deloitte & Touche dismissed as independent auditor effective Aug 2, 2024; prior reports contained going concern explanatory paragraph.
-
Celularity receives Nasdaq delisting notice for late Q1 2024 10-Q and 2023 10-K
Nasdaq notified Celularity on May 21, 2024 of non-compliance with Listing Rule 5250(c)(1) for delinquent Q1 2024 10-Q and 2023 10-K.
-
Celularity guides Q4 2023 revenue ~$12.1M, Q1 2024 revenue ~$14.8M
Preliminary Q4 2023 net revenue ~$12.1M from biomaterial product sales and biobanking services.
-
Celularity receives Nasdaq delisting notice for late 10-K filing; must submit plan by June 17
Failed to file 2023 Form 10-K by April 15 extension; Nasdaq notified on April 17, 2024.
-
Celularity signs $10M standby equity deal and $3.15M convertible note with Yorkville
SEPA allows Celularity to sell up to $10M of common stock to Yorkville over 36 months at 97% of VWAP.
-
Celularity approves 1-for-10 reverse stock split; warrant issuance to RWI fails
Board set reverse split ratio at 1-for-10, effective 5:00 PM ET on Feb 28, 2024.
Executive changes
Appointed
Rick Gonzalez
Chief Commercial Officer
CELU ·
Celularity Inc
On May 29, 2026, Celularity Inc. (“Celularity”) appointed Rick Gonzalez as Chief Commercial Officer of Celularity.
Departed
David Beers
Chief Financial Officer
CELU ·
Celularity Inc
terminated the employment of David Beers, its Chief Financial Officer without cause
Appointed
(interim)
Joseph DosSantos
interim CFO
CELU ·
Celularity Inc
appointed Joseph DosSantos, its current Senior Vice President Finance, as the Company's interim CFO while the Company conducts a search for a new CFO.
Appointed
Vincent LeVien
Class II director
CELU ·
Celularity Inc
On June 5, 2025, the Board of Directors of Celularity Inc. (the “Company”) appointed Vincent LeVien as a Class II director of the Company to serve until the Annual Meeting of Stockholders to be held in 2026.
Departed
Dean Kehler
director
CELU ·
Celularity Inc
On May 14, 2025, Dean Kehler, a director of Celularity Inc. (the “Company”), resigned as a member of the Board of Directors of the Company.
Departed
Adrian Kilcoyne
Executive Vice President and Chief Medical Officer
CELU ·
Celularity Inc
Adrian Kilcoyne, M.D., M.P.H., M.B.A. of Celularity Inc., or Celularity, provided notice of resignation from his role as Executive Vice President and Chief Medical Officer, effective as of August 6, 2024, to pursue other opportunities.
Appointed
Richard J. Berman
Director
CELU ·
Celularity Inc
On August 27, 2024, the board of directors, or the Board, of Celularity Inc., or Celularity, appointed Richard J. Berman, as a Class II director to fill the vacancy left by the resignation of Robin L. Smith, M.D.
Departed
Marc Mazur
Director
CELU ·
Celularity Inc
On July 31, 2024, Marc Mazur, a Class III member of the Board of Directors of Celularity, notified the Board of Directors of his intention to resign as a member of the board and all committees thereof effective July 31, 2024.
Departed
Robin L. Smith, MD
Class II member of the board of directors
CELU ·
Celularity Inc
On December 24, 2023, Robin L. Smith, MD, a Class II member of the board of directors of Celularity Inc., or Celularity, notified the board of directors of her intention to resign as a member of the board effective December 24, 2023.
Departed
Lim Kok Thay
Class II member of the board of directors
CELU ·
Celularity Inc
On September 14, 2023, Lim Kok Thay, a Class II member of the board of directors of the Company, notified the board of his intention to resign as a member of the board and all committees thereof effective immediately.
Appointed
Geoffrey Shiu Fei Ling
Class I Director
CELU ·
Celularity Inc
the board appointed Geoffrey Shiu Fei Ling, M.D., as a Class I director to fill the vacancy left by the resignation of Dr. von Eschenbach, to serve until his successor is elected and qualified
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material